OBJECTIVE: Glioblastomais is one of the main universal, primary brain cancers, in adults, that has an extremely poor clinical prognosis and a median living period of 12-15 months, accounting for nearly 3-4% of all cancer-related deaths. MicroRNAs (miRNAs) play key roles in cancer pathogenesis by binding the specific and complementary sequences of the 3'UTR of target mRNAs to regulate protein synthesis. Therefore, recognizing functional miRNAs and the fundamental molecular mechanisms will offer novel evidences for the progress of targeted malignancy interferences. Our current study intended to explore the function of miR-28-5p in the promotion of the glioblastoma. METHODS: Human glioblastoma tissues, paired nearby normal/non-tumor tissues were accumulated from our hospital. Human glioblastoma SNB19 cells were infected by miR-28-5p mimics or miR-28-5p siRNA by lentivirus. Tumor spheres formation was used to evaluate the growth ability. MTT examine was applied for measuring viability. BrdU cell proliferation assay was applied to uncover the proliferation ability of SNB19 glioblastoma cells. Real-time PCR was conducted to identify miRNA expression. Western blot analysis was employed to measure protein expression. Dual-luciferase FOXO1-3'UTR reporter was used to determine the ability of miR-28-5p to regulate FOXO1. RESULTS: Expression of miR-28-5p was explored to be increased in both human glioblastoma tissues and cell lines. Up-regulated miR-28-5p expression promotes tumor spheres formation, cell viability, and proliferation ability of glioblastoma cells. FOXO1 was found to be the target of miR-28-5p and the activity of FOXO1 was down-regulated by miR-28-5p in glioblastoma cells. CONCLUSIONS: MiR-28-5p is an oncogene and promotes the occurrence of glioblastoma by directly targeting the FOXO1. IJCEP
OBJECTIVE: Glioblastomais is one of the main universal, primary brain cancers, in adults, that has an extremely poor clinical prognosis and a median living period of 12-15 months, accounting for nearly 3-4% of all cancer-related deaths. MicroRNAs (miRNAs) play key roles in cancer pathogenesis by binding the specific and complementary sequences of the 3'UTR of target mRNAs to regulate protein synthesis. Therefore, recognizing functional miRNAs and the fundamental molecular mechanisms will offer novel evidences for the progress of targeted malignancy interferences. Our current study intended to explore the function of miR-28-5p in the promotion of the glioblastoma. METHODS:Humanglioblastoma tissues, paired nearby normal/non-tumor tissues were accumulated from our hospital. HumanglioblastomaSNB19 cells were infected by miR-28-5p mimics or miR-28-5p siRNA by lentivirus. Tumor spheres formation was used to evaluate the growth ability. MTT examine was applied for measuring viability. BrdU cell proliferation assay was applied to uncover the proliferation ability of SNB19glioblastoma cells. Real-time PCR was conducted to identify miRNA expression. Western blot analysis was employed to measure protein expression. Dual-luciferase FOXO1-3'UTR reporter was used to determine the ability of miR-28-5p to regulate FOXO1. RESULTS: Expression of miR-28-5p was explored to be increased in both humanglioblastoma tissues and cell lines. Up-regulated miR-28-5p expression promotes tumor spheres formation, cell viability, and proliferation ability of glioblastoma cells. FOXO1 was found to be the target of miR-28-5p and the activity of FOXO1 was down-regulated by miR-28-5p in glioblastoma cells. CONCLUSIONS:MiR-28-5p is an oncogene and promotes the occurrence of glioblastoma by directly targeting the FOXO1. IJCEP
Authors: N Galili; R J Davis; W J Fredericks; S Mukhopadhyay; F J Rauscher; B S Emanuel; G Rovera; F G Barr Journal: Nat Genet Date: 1993-11 Impact factor: 38.330
Authors: Maximilian Niyazi; Franz Zehentmayr; Olivier M Niemöller; Sabina Eigenbrod; Hans Kretzschmar; Klaus Schulze-Osthoff; Jörg-Christian Tonn; Mike Atkinson; Simone Mörtl; Claus Belka Journal: Radiat Oncol Date: 2011-11-10 Impact factor: 3.481
Authors: Karishma R Rajani; Lucas P Carlstrom; Ian F Parney; Aaron J Johnson; Arthur E Warrington; Terry C Burns Journal: Front Oncol Date: 2019-02-22 Impact factor: 6.244
Authors: José María Sayagués; Luís Antonio Corchete; María Laura Gutiérrez; Maria Eugenia Sarasquete; María Del Mar Abad; Oscar Bengoechea; Encarna Fermiñán; María Fernanda Anduaga; Sofia Del Carmen; Manuel Iglesias; Carmen Esteban; María Angoso; Jose Antonio Alcazar; Jacinto García; Alberto Orfao; Luís Muñoz-Bellvis Journal: Oncotarget Date: 2016-11-08